终末期心力衰竭患者药物治疗后ICAM-1、NGAL及NT-proBNP水平变化  

Changes of ICAM-1,NGAL and NT-proBNP levels in patients with end-stage heart failure after drug treatment

作　　者：林仕钦[1] 卓剑[1] 李伟 LIN Shiqin;ZHUO Jian;LI Wei(Department of Emergency ICU,Wanning People's Hospital,Wanning,Hainan,China,571500)

机构地区：[1]海南省万宁市人民医院急诊ICU,海南万宁571500

出　　处：《分子诊断与治疗杂志》2023年第1期69-72,76,共5页Journal of Molecular Diagnostics and Therapy

基　　金：海南省科技计划项目(2019wnkj23)。

摘　　要：目的 研究心脉隆注射液联合环磷腺苷葡胺治疗终末期心力衰竭患者中性粒细胞明胶酶相关脂质运载蛋白(NGAL)、细胞间黏附分子-1(ICAM-1)及血浆N末端脑钠肽前体(NT-proBNP)水平变化情况。方法 收集2019年2月至2020年12月海南省万宁市人民医院收治的208例终末期心力衰竭患者的临床资料。根据不同治疗方案分为单一组(n=102例,环磷腺苷葡胺)与联合组(n=106例,心脉隆注射液联合环磷腺苷葡胺)。比较两组临床疗效、心功能指标[左心室舒张末期内径(LVEDD)、左心室收缩末期内径(LVESD)、左室射血分数(LVEF)、ICAM-1、NGAL及NT-proBNP]及不良反应发生率。结果 联合组治疗后总有效率为94.34%,显著高于单一组的76.47%,差异具有统计学意义(P<0.05)。治疗后,两组LVEDD、LVESD及ICAM-1、NGAL、NT-proBNP均较治疗前下降,LVEF均较治疗前上升,且联合组LVEDD、LVESD及ICAM-1、NGAL、NT-proBNP均低于单一组,LVEF高于单一组,差异均有统计学意义(P<0.05)。联合组不良反应总发生率为11.32%,单一组不良反应总发生率为9.80%,差异无统计学意义(P>0.05)。结论 心脉隆注射液联合环磷腺苷葡胺治疗终末期心力衰竭患者的疗效确切,可有效改善患者心功能,且具有较高的安全性。Objective To study the changes in neutrophil gelatinase associated lipocalin(NGAL),intercellular adhesion molecule-1(ICAM-1)and plasma N-terminal pro brain natriuretic peptide(NT-proBNP)levels in patients with end-stage heart failure treated with Xinmailong injection combined with meglumine adenosine cyclophosphate. Methods The clinical data of 208 patients with end-stage heart failure admitted to Wanning People’s Hospital of Hainan Province from February 2019 to December 2020 were collected. According to different treatment plans,they were divided into a single group(n=102 cases,meglumine adenosine cyclophosphate)and a combined group(n=106 cases,Xinmailong injection combined with meglumine adenosine cyclophosphate). The clinical efficacy and cardiac function indexes [Left ventricular end diastolic diameter(LVEDD),left ventricular end systolic diameter(LVESD),and left ventricular ejection fraction(LVEF),ICAM-1,NGAL and NT-proBNP]and the incidence of adverse reactions were compared between the two groups. Results The total effective rate of the combined group after treatment was 94.34%,which was significantly higher than that of the single group(76.47%),and the difference was statistically significant(P<0.05).After treatment,LVEDD,LVESD,ICAM-1,NGAL,and NT-proBNP in both groups decreased compared with those before treatment,and LVEF increased compared with those before treatment,and the LVEDD,LVESD,ICAM-1,NGAL and NT-proBNP in the combined group were lower than those before treatment. In the single group,the LVEF was higher than that in the single group,and the differences were statistically significant(P<0.05). The total incidence of adverse reactions in the combined group was 11.32%,and that in the single group was 9.80%,the difference was not statistically significant(P>0.05). Conclusion Xinmailong injection combined with meglumine adenosine cyclophosphate has a definite curative effect in the treatment of patients with end-stage heart failure,can effectively improve the heart function of patients with high sa

关 键 词：心脉隆注射液 环磷腺苷葡胺 终末期心力衰竭 心功能指标 

分 类 号：R541.6[医药卫生—心血管疾病]